Patents vs. Patients: How 136 Drug Monopolies Block Your Access to Che

A senator asks the CEO of AbbVie how many patents his company holds on Humira. The answer: 136. This isn't a mistake—it's a strategy. While patients wait for cheaper alternatives, the pharmaceutical industry uses the patent system to extend monopolies and keep prices high. Today, I'll explain how this trap works and what you can do to protect your wallet and your health.

The Science

The story begins with Humira (adalimumab), a monoclonal antibody that treats inflammatory diseases like rheumatoid arthritis and inflammatory bowel disease. Its original patent expired in 2016, but AbbVie managed to extend exclusivity until 2023 through a web of 136 secondary patents. These don't protect the drug itself, but rather aspects like treatment methods, formulations, or manufacturing processes. The result: 18 additional years without biosimilar competition.

Biosimilars are nearly identical versions of biologic drugs, but cost 20% to 30% less. In Europe, where secondary patents are weaker, Humira biosimilars arrived years earlier and reduced prices by up to 80%. In the U.S., the 'patent thicket' strategy delayed competitor entry, keeping prices high for patients and health systems.

“One molecule can generate 136 patents, but only one real innovation.”

Key Findings

• Patent Count: AbbVie accumulated 136 patents for Humira, as stated by the CEO in a 2019 Senate hearing.
• Monopoly Extension: The original patent expired in 2016, but secondary patents extended exclusivity until 2023, adding 18 more years.
• Price Impact: Biosimilars can cost 20% to 30% less than the original drug; in Europe, competition reduced prices by up to 80%.
• Thicket Strategy: The 136 patents cover therapeutic uses, formulations, and processes—not the original molecule.

Why It Matters

This practice isn't unique to AbbVie. Many pharmaceutical companies use 'evergreening' to extend monopolies on successful drugs. The result: patients pay more for medications that could be much cheaper. For those with chronic conditions like rheumatoid arthritis, this can mean out-of-pocket costs of thousands of dollars per year.

The mechanism is perverse: the patent system was designed to incentivize innovation, but here it's used to block it. Secondary patents rarely represent significant therapeutic advances; they are legal barriers. Meanwhile, biosimilars—which are innovations in themselves (more efficient manufacturing, lower costs)—are kept off the market.

For the biohacker or informed patient, this means that the 'innovation' you hear in pharmaceutical ads may be just a marketing strategy. Real innovation happens when prices drop and access improves.

Your Protocol

If you take a biologic drug or are considering one, here are practical steps to navigate this system:

1. 1Ask about biosimilars: When your doctor prescribes a biologic, ask if an approved biosimilar exists. In the U.S., many Humira biosimilars have been available since 2023.
2. 2Check patents: Use tools like the FDA's Orange Book database to identify when secondary patents expire. This helps you plan treatment switches.
3. 3Compare costs: Before filling a prescription, check with your insurance or pharmacy the price of brand vs. biosimilar. The difference can be significant.
4. 4Talk to your pharmacist: They often know what alternatives are available and can help you request substitution if allowed.

What To Watch Next

The Biosimilar Competition Act proposed in the U.S. Congress aims to limit patent evergreening. If passed, it could accelerate biosimilar entry and reduce prices. Additionally, the FTC has shown interest in investigating anticompetitive practices in the pharmaceutical industry.

On the scientific front, biosimilars are emerging for other blockbuster drugs, including cancer and autoimmune treatments. Keep an eye on FDA approvals, especially for drugs with expiring patents.

The Bottom Line

Humira's 136 patents aren't innovation—they're a legal wall delaying access to affordable treatments. As a patient or biohacker, your best defense is information: know your biosimilars, ask your doctor, and compare prices. True health innovation isn't just about discovering new molecules—it's about making sure they reach those who need them. The future of affordable medicine depends on dismantling these patent traps, one molecule at a time.

Expanded Context

The Humira case is not isolated. A 2020 study found that 80% of the top-selling biologic drugs in the U.S. have at least one secondary patent after the primary patent expires. On average, these extensions add 6 years of monopoly. For diseases like psoriasis or ulcerative colitis, where biologics are the standard of care, this translates to annual costs that can exceed $50,000 per patient. The lack of competition not only affects wallets but also limits access to treatments that could improve quality of life.

Moreover, the patent thicket strategy disproportionately impacts vulnerable populations. Uninsured or underinsured patients suffer the most from high prices, often delaying or abandoning treatments. In low- and middle-income countries, where biosimilars could be a cost-effective solution, secondary patents hinder local production.

Emerging Research

Recently, the U.S. Federal Trade Commission (FTC) has intensified scrutiny of patent listings in the Orange Book. In 2024, the FTC sent letters to several pharmaceutical companies questioning the validity of secondary patents. Additionally, a 2025 Harvard University study suggests that secondary patents on biologics are 3 times more likely to be declared invalid in court than primary patents. This opens a window for biosimilar manufacturers to challenge these barriers.

In Europe, the European Medicines Agency (EMA) has approved over 70 biosimilars since 2006, and prices have dropped by up to 90% in some cases. The lesson is clear: when secondary patents are weak, competition flourishes. In the U.S., the approval of Humira biosimilars in 2023 has already begun to lower prices, albeit slowly. The U.S. biosimilar market is expected to reach $30 billion by 2027.

Patient Perspective

Maria, a 45-year-old patient with rheumatoid arthritis, paid $3,000 per month for Humira before biosimilars became available. After switching to a biosimilar in 2024, her cost dropped to $600. "I not only saved money, but my treatment is just as effective," she says. Stories like Maria's are becoming more common, but barriers remain: some doctors are reluctant to prescribe biosimilars due to lack of familiarity or deals with brand-name companies.

For the biohacker, the key is self-education. Knowing patent expiration dates and biosimilar approvals can make a big difference in treatment costs. Additionally, joining patient advocacy groups can help push for legislative changes.

Systemic Impact Analysis

Biologic drug costs in the U.S. account for 40% of total prescription drug spending, despite comprising only 2% of prescriptions. If biosimilars achieved penetration similar to Europe, savings could reach $100 billion over a decade. However, evergreening tactics and 'pay-for-delay' agreements (where the brand manufacturer pays the generic to delay entry) remain obstacles.

The Biosimilar Competition Act, introduced in 2025, proposes limiting secondary patents to one per drug and banning pay-for-delay agreements. Although its passage is uncertain, the debate has brought the issue to the public agenda. Meanwhile, some states have passed laws allowing pharmacists to automatically substitute a biosimilar for the brand biologic unless the doctor specifies otherwise.

The Bottom Line

Humira's 136 patents aren't innovation—they're a legal wall delaying access to affordable treatments. As a patient or biohacker, your best defense is information: know your biosimilars, ask your doctor, and compare prices. True health innovation isn't just about discovering new molecules—it's about making sure they reach those who need them. The future of affordable medicine depends on dismantling these patent traps, one molecule at a time.